ES2258071T3 - Utilizacion de mirtazepina para trastornos del sueño. - Google Patents

Utilizacion de mirtazepina para trastornos del sueño.

Info

Publication number
ES2258071T3
ES2258071T3 ES01902410T ES01902410T ES2258071T3 ES 2258071 T3 ES2258071 T3 ES 2258071T3 ES 01902410 T ES01902410 T ES 01902410T ES 01902410 T ES01902410 T ES 01902410T ES 2258071 T3 ES2258071 T3 ES 2258071T3
Authority
ES
Spain
Prior art keywords
mirtazapine
sleep
treatment
dose
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01902410T
Other languages
English (en)
Spanish (es)
Inventor
Gerardus Stephanus Franciscus Ruigt
Frans Van Den Berg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2258071T3 publication Critical patent/ES2258071T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES01902410T 2000-02-11 2001-02-06 Utilizacion de mirtazepina para trastornos del sueño. Expired - Lifetime ES2258071T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200499 2000-02-11
EP00200499 2000-02-11

Publications (1)

Publication Number Publication Date
ES2258071T3 true ES2258071T3 (es) 2006-08-16

Family

ID=8171013

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01902410T Expired - Lifetime ES2258071T3 (es) 2000-02-11 2001-02-06 Utilizacion de mirtazepina para trastornos del sueño.

Country Status (25)

Country Link
US (1) US6933293B2 (cg-RX-API-DMAC7.html)
EP (4) EP2283840A1 (cg-RX-API-DMAC7.html)
JP (1) JP5039994B2 (cg-RX-API-DMAC7.html)
KR (1) KR20020069371A (cg-RX-API-DMAC7.html)
CN (2) CN101229170A (cg-RX-API-DMAC7.html)
AR (1) AR027394A1 (cg-RX-API-DMAC7.html)
AT (1) ATE317261T1 (cg-RX-API-DMAC7.html)
AU (1) AU780439B2 (cg-RX-API-DMAC7.html)
BR (1) BR0108261A (cg-RX-API-DMAC7.html)
CA (1) CA2396209C (cg-RX-API-DMAC7.html)
CO (1) CO5271706A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ302368B6 (cg-RX-API-DMAC7.html)
DE (1) DE60117122T2 (cg-RX-API-DMAC7.html)
DK (1) DK1257278T3 (cg-RX-API-DMAC7.html)
ES (1) ES2258071T3 (cg-RX-API-DMAC7.html)
HK (1) HK1049122B (cg-RX-API-DMAC7.html)
HU (1) HUP0204391A3 (cg-RX-API-DMAC7.html)
IL (2) IL150290A0 (cg-RX-API-DMAC7.html)
NO (1) NO328007B1 (cg-RX-API-DMAC7.html)
PE (1) PE20011080A1 (cg-RX-API-DMAC7.html)
PL (1) PL206073B1 (cg-RX-API-DMAC7.html)
RU (1) RU2270680C2 (cg-RX-API-DMAC7.html)
SK (1) SK287396B6 (cg-RX-API-DMAC7.html)
WO (1) WO2001058453A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200205238B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152055A1 (en) * 2003-01-30 2004-08-05 Gliessner Michael J.G. Video based language learning system
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
WO2005051349A2 (en) * 2003-11-25 2005-06-09 Aurobindo Pharma Ltd. Pharmaceutical compositions of mirtazapine
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
AU2005292853C1 (en) * 2004-10-14 2010-08-05 Daikin Industries, Ltd. Atmosphere modifying method and spray agent and spray device used in the same
JP2006137748A (ja) * 2004-10-14 2006-06-01 Daikin Ind Ltd 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置
JP2007284363A (ja) * 2006-04-13 2007-11-01 Daikin Ind Ltd 噴霧剤
WO2008125578A2 (en) 2007-04-11 2008-10-23 N.V. Organon A method for the preparation of mirtazapine
SI3261645T1 (sl) 2015-02-27 2021-08-31 Dechra Limited Stimulacija apetita, uravnavanje izgube mase in zdravljenje anoreksije pri psih in mačkah
CN111053735A (zh) * 2020-02-25 2020-04-24 上海阶平医院管理有限公司 一种治疗失眠的冷敷凝胶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
JPH08502049A (ja) * 1992-10-07 1996-03-05 アクゾ ノーベル ナムローゼ フェンノートシャップ ラセミ体混合物からエナンチオマーを分離する方法
EP0813873B1 (en) * 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ATE289816T1 (de) 1997-11-14 2005-03-15 Akzo Nobel Nv Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen

Also Published As

Publication number Publication date
NO328007B1 (no) 2009-11-09
EP1257278A1 (en) 2002-11-20
US6933293B2 (en) 2005-08-23
NO20023803L (no) 2002-10-09
CZ302368B6 (cs) 2011-04-13
ATE317261T1 (de) 2006-02-15
IL150290A0 (en) 2002-12-01
RU2002124141A (ru) 2004-03-10
DE60117122D1 (de) 2006-04-20
PL356721A1 (en) 2004-06-28
CN101229170A (zh) 2008-07-30
DK1257278T3 (da) 2006-06-12
CZ20022330A3 (cs) 2002-11-13
HK1049122A1 (en) 2003-05-02
HK1049122B (en) 2006-04-21
HUP0204391A3 (en) 2005-03-29
JP5039994B2 (ja) 2012-10-03
AU780439B2 (en) 2005-03-24
JP2003522147A (ja) 2003-07-22
EP1257278B1 (en) 2006-02-08
BR0108261A (pt) 2003-03-05
ZA200205238B (en) 2003-09-29
WO2001058453A1 (en) 2001-08-16
IL150290A (en) 2010-12-30
CO5271706A1 (es) 2003-04-30
EP1656937A1 (en) 2006-05-17
SK287396B6 (sk) 2010-08-09
CN1395487A (zh) 2003-02-05
PL206073B1 (pl) 2010-06-30
AR027394A1 (es) 2003-03-26
DE60117122T2 (de) 2006-07-27
NO20023803D0 (no) 2002-08-09
RU2270680C2 (ru) 2006-02-27
HUP0204391A2 (en) 2003-05-28
EP2283840A1 (en) 2011-02-16
CA2396209A1 (en) 2001-08-16
CA2396209C (en) 2009-09-01
EP1658850A1 (en) 2006-05-24
SK11442002A3 (sk) 2003-02-04
US20030022888A1 (en) 2003-01-30
KR20020069371A (ko) 2002-08-30
PE20011080A1 (es) 2001-10-18
AU3024701A (en) 2001-08-20

Similar Documents

Publication Publication Date Title
Grinspoon et al. Psychotherapy and pharmacotherapy in chronic schizophrenia
ES2258071T3 (es) Utilizacion de mirtazepina para trastornos del sueño.
US20080182890A1 (en) Methods of using low-dose doxepin for the improvement of sleep
EP0282818B1 (en) The use of gepirone for preparing a pharmaceutical composition for the treatment of atypical depression
JPH0920666A (ja) 成熟遅延および類似疾患の治療用医薬組成物
Winsberg et al. Pharmacologic management of children with hyperactive/aggressive/inattentive behavior disorders: Suggestions for the pediatrician
Mendelson Pharmacotherapy of insomnia
EP0440851A1 (en) Use of buspirone for the treatment of depressions
HK1087359A (en) The use of mirtazapine for the treatment of sleep disorders
Laddha et al. Drugs impairment on driving performance: an overview
HK1150978A (en) The use of mirtazapine for the treatment of sleep disorders
Ormerod et al. Terfenadine and brompheniramine maleate in urticaria and dermographism
HK1087356A (en) The use of mirtazapine for the treatment of sleep disorders
TWI297607B (en) The use of mirtazapine for the treatment of sleep disorders and pharmaceutical composition comprising mirtazapine
EP4376954A1 (en) Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
MXPA02006710A (en) The use of mirtazapine for the treatment of sleep disorders
CN120437129A (zh) 组合物在制备用于改善认知能力方面的药物中的用途
Martin Current status of imipramine